百克生物启动HSV-2 mRNA疫苗Ⅰ期临床试验

Core Viewpoint - The initiation of the Phase I dose-escalation trial for the HSV-2 mRNA vaccine by Baike Biotech marks a significant step in addressing genital herpes, focusing on safety, tolerability, and immunogenicity among participants aged 18 to 55 [1] Group 1: Trial Details - The trial was successfully launched at Beijing Jishuitan Hospital on September 9 [1] - The meeting included systematic training and work deployment on key topics such as the background of genital herpes disease, vaccine development, GCP standards, clinical trial protocols, investigator manuals, sample management, and on-site processes [1] - The preparation for various tasks is progressing smoothly, with participant enrollment set to commence shortly [1]